Connect your AI

SELLAS Life Sciences Group, Inc. SLS Q4 2024 Annual earnings

Reported March 20, 2025 · Before market open

Diluted EPS-$0.08Beat by $0.03

EPS estimate-$0.11

Next report

Aug 11, 2026 (In 4 weeks)

EPS estimate-$0.05

Financials

Q4 2024

Income statement

Operating income-$6.9M+15.4%

Net income-$6.7M+17.2%

EPS (diluted)-$0.08+68.0%

Balance sheet

Cash & equivalents$13.9M+449%

Total debt$1.0M+10.5%

Total equity$9.5M+219%

Total assets$19.4M+212%

Cash flow

Operating cash flow-$7.2M-48.2%

Valuation & ratios

Valuation

as of 12/31/24

Market cap$73.2M+115%

Enterprise value$60.31M+86.4%

Returns & leverage

Debt / equity0.1×—

Current ratio1.7×+1.5×

Versus estimates

Diluted EPS

Q1 2026-$0.05Beat by $0.01 Q4 2025-$0.05Beat by $0.01 Q3 2025-$0.06Beat by $0.00 Q2 2025-$0.07Beat by $0.01 Q1 2025-$0.07Beat by $0.03

Q4 2024-$0.08Beat by $0.03

Ask the moment SELLAS Life Sciences Group, Inc. reports.

Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.

Connect your AI

Harbor at dusk

Questions, answered.

When did SELLAS Life Sciences Group, Inc. report Q4 2024 earnings?: SELLAS Life Sciences Group, Inc. (SLS) reported Q4 2024 earnings on March 20, 2025 before market open.
What were SELLAS Life Sciences Group, Inc.'s Q4 2024 revenue and EPS?: SELLAS Life Sciences Group, Inc. reported diluted EPS of $-0.08 for Q4 2024.
Did SELLAS Life Sciences Group, Inc. beat estimates in Q4 2024?: EPS beat the consensus estimate of $-0.11 by $0.03.
Where can I find SELLAS Life Sciences Group, Inc.'s Q4 2024 SEC filings?: You can read the 10-K periodic report (0001390478-25-000003) directly on SEC EDGAR. The filing index links above go to sec.gov.